364 related articles for article (PubMed ID: 20823825)
21. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
[TBL] [Abstract][Full Text] [Related]
22. Sertraline in the treatment of neurotic excoriations and related disorders.
Kalivas J; Kalivas L; Gilman D; Hayden CT
Arch Dermatol; 1996 May; 132(5):589-90. PubMed ID: 8624163
[No Abstract] [Full Text] [Related]
23. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Bailly D
Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
[TBL] [Abstract][Full Text] [Related]
24. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
[TBL] [Abstract][Full Text] [Related]
25. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
[TBL] [Abstract][Full Text] [Related]
26. Insight and treatment outcome in obsessive-compulsive disorder.
Eisen JL; Rasmussen SA; Phillips KA; Price LH; Davidson J; Lydiard RB; Ninan P; Piggott T
Compr Psychiatry; 2001; 42(6):494-7. PubMed ID: 11704942
[TBL] [Abstract][Full Text] [Related]
27. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder.
Wagner KD; Cook EH; Chung H; Messig M
J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S53-60. PubMed ID: 12880500
[TBL] [Abstract][Full Text] [Related]
28. Should young people be given antidepressants? No.
Timimi S
BMJ; 2007 Oct; 335(7623):751. PubMed ID: 17932206
[TBL] [Abstract][Full Text] [Related]
29. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression.
Möller HJ; Gallinat J; Hegerl U; Arató M; Janka Z; Pflug B; Bauer H
Pharmacopsychiatry; 1998 Sep; 31(5):170-7. PubMed ID: 9832348
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
31. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
[TBL] [Abstract][Full Text] [Related]
32. Sertraline in the treatment of anxiety disorders.
Hirschfeld RM
Depress Anxiety; 2000; 11(4):139-57. PubMed ID: 10945134
[TBL] [Abstract][Full Text] [Related]
33. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.
Ekselius L; von Knorring L
Int Clin Psychopharmacol; 1998 Sep; 13(5):205-11. PubMed ID: 9817625
[TBL] [Abstract][Full Text] [Related]
34. [Selective serotonin reuptake inhibitor(SSRI)].
Motohashi N
Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
[TBL] [Abstract][Full Text] [Related]
35. Addition of trazodone to sertraline: a probable synergistic action in a case of obsessive-compulsive disorder.
Rocha FF; Corrêa H; Lage NV
Braz J Psychiatry; 2007 Dec; 29(4):381-2. PubMed ID: 18200402
[No Abstract] [Full Text] [Related]
36. Sertraline and venlafaxine: new indication. Prevention of recurrent depression: no advance.
Prescrire Int; 2005 Feb; 14(75):19-20. PubMed ID: 15751171
[TBL] [Abstract][Full Text] [Related]
37. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
Besiroglu L; Çetinkaya N; Selvi Y; Atli A
Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
[TBL] [Abstract][Full Text] [Related]
38. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
Koran LM; Mueller K; Maloney A
J Clin Psychopharmacol; 1996 Jun; 16(3):253-4. PubMed ID: 8784659
[No Abstract] [Full Text] [Related]
39. Relapse of depressive symptoms after discontinuing sertraline.
Baldessarini RJ; Viguera AC
JAMA; 1999 Jul; 282(4):323-4. PubMed ID: 10432022
[No Abstract] [Full Text] [Related]
40. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy.
Alderman J; Wolkow R; Chung M; Johnston HF
J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):386-94. PubMed ID: 9549959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
